Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

68 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and Immunogenicity of an Inactivated Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine in a Subgroup of Healthy Adults in Chile.
Bueno SM, Abarca K, González PA, Gálvez NMS, Soto JA, Duarte LF, Schultz BM, Pacheco GA, González LA, Vázquez Y, Ríos M, Melo-González F, Rivera-Pérez D, Iturriaga C, Urzúa M, Domínguez A, Andrade CA, Berríos-Rojas RV, Canedo-Marroquín G, Covián C, Moreno-Tapia D, Saavedra F, Vallejos OP, Donato P, Espinoza P, Fuentes D, González M, Guzmán P, Muñoz Venturelli P, Pérez CM, Potin M, Rojas Á, Fasce RA, Fernández J, Mora J, Ramírez E, Gaete-Argel A, Oyarzún-Arrau A, Valiente-Echeverría F, Soto-Rifo R, Weiskopf D, Sette A, Zeng G, Meng W, González-Aramundiz JV, Kalergis AM. Bueno SM, et al. Among authors: iturriaga c. Clin Infect Dis. 2022 Aug 24;75(1):e792-e804. doi: 10.1093/cid/ciab823. Clin Infect Dis. 2022. PMID: 34537835 Free PMC article. Clinical Trial.
Safety and immunogenicity evaluation of recombinant BCG vaccine against respiratory syncytial virus in a randomized, double-blind, placebo-controlled phase I clinical trial.
Abarca K, Rey-Jurado E, Muñoz-Durango N, Vázquez Y, Soto JA, Gálvez NMS, Valdés-Ferrada J, Iturriaga C, Urzúa M, Borzutzky A, Cerda J, Villarroel L, Madrid V, González PA, González-Aramundiz JV, Bueno SM, Kalergis AM. Abarca K, et al. Among authors: iturriaga c. EClinicalMedicine. 2020 Oct 6;27:100517. doi: 10.1016/j.eclinm.2020.100517. eCollection 2020 Oct. EClinicalMedicine. 2020. PMID: 33073219 Free PMC article.
A cluster randomized trial of interferon ß-1a for the reduction of transmission of SARS-Cov-2: protocol for the Containing Coronavirus Disease 19 trial (ConCorD-19).
Iturriaga C, Eiffler N, Aniba R, Ben-Othman R, Perez-Mateluna G, Meyer JKV, Fish EN, Kollmann TR, Severino N, Stick S, Borzutzky A, Perret C, Castro-Rodriguez JA, Garcia-Huidobro D. Iturriaga C, et al. BMC Infect Dis. 2021 Aug 13;21(1):814. doi: 10.1186/s12879-021-06519-4. BMC Infect Dis. 2021. PMID: 34388972 Free PMC article.
Prevalence of filaggrin loss-of-function variants in Chilean population with and without atopic dermatitis.
Cárdenas GV, Iturriaga C, Hernández CD, Tejos-Bravo M, Pérez-Mateluna G, Cabalin C, Urzúa M, Venegas-Salas LF, Fraga JP, Rebolledo B, Poli MC, Repetto GM, Casanello P, Castro-Rodríguez JA, Borzutzky A. Cárdenas GV, et al. Among authors: iturriaga c. Int J Dermatol. 2022 Mar;61(3):310-315. doi: 10.1111/ijd.15887. Epub 2021 Sep 4. Int J Dermatol. 2022. PMID: 34480753
Immune Profile and Clinical Outcome of Breakthrough Cases After Vaccination With an Inactivated SARS-CoV-2 Vaccine.
Duarte LF, Gálvez NMS, Iturriaga C, Melo-González F, Soto JA, Schultz BM, Urzúa M, González LA, Vázquez Y, Ríos M, Berríos-Rojas RV, Rivera-Pérez D, Moreno-Tapia D, Pacheco GA, Vallejos OP, Hoppe-Elsholz G, Navarrete MS, Rojas Á, Fasce RA, Fernández J, Mora J, Ramírez E, Zeng G, Meng W, González-Aramundiz JV, González PA, Abarca K, Bueno SM, Kalergis AM. Duarte LF, et al. Among authors: iturriaga c. Front Immunol. 2021 Sep 29;12:742914. doi: 10.3389/fimmu.2021.742914. eCollection 2021. Front Immunol. 2021. PMID: 34659237 Free PMC article. Clinical Trial.
Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine.
Melo-González F, Soto JA, González LA, Fernández J, Duarte LF, Schultz BM, Gálvez NMS, Pacheco GA, Ríos M, Vázquez Y, Rivera-Pérez D, Moreno-Tapia D, Iturriaga C, Vallejos OP, Berríos-Rojas RV, Hoppe-Elsholz G, Urzúa M, Bruneau N, Fasce RA, Mora J, Grifoni A, Sette A, Weiskopf D, Zeng G, Meng W, González-Aramundiz JV, González PA, Abarca K, Ramírez E, Kalergis AM, Bueno SM. Melo-González F, et al. Among authors: iturriaga c. Front Immunol. 2021 Nov 9;12:747830. doi: 10.3389/fimmu.2021.747830. eCollection 2021. Front Immunol. 2021. PMID: 34858404 Free PMC article. Clinical Trial.
Safety and Non-Inferiority Evaluation of Two Immunization Schedules with an Inactivated SARS-CoV-2 Vaccine in Adults: A Randomized Clinical Trial.
Abarca K, Iturriaga C, Urzúa M, Le Corre N, Pineda A, Fernández C, Domínguez A, González PA, Bueno SM, Donato P, Espinoza P, Fuentes D, González M, Guzmán P, Muñoz-Venturelli P, Pérez CM, Potin M, Rojas Á, González-Aramundiz JV, Gálvez NMS, Aguirre-Boza F, Aljaro S, Bátiz LF, Campisto Y, Cepeda M, Cortés A, López S, Pérez ML, Schilling A, Kalergis AM, On Behalf Of The CoronaVac Cl Study Group. Abarca K, et al. Among authors: iturriaga c. Vaccines (Basel). 2022 Jul 6;10(7):1082. doi: 10.3390/vaccines10071082. Vaccines (Basel). 2022. PMID: 35891246 Free PMC article.
68 results